Stocks
Neurocrine Biosciences, Inc.NBIX
NASDAQHealthcareBiotechnology$129.78+1.57%
Focused on developing therapies for neurological, neuroendocrine, and psychiatric disorders, the company commercializes and advances small‑molecule drugs targeting conditions with limited treatment options. Its flagship product, Ingrezza, is approved in the U.S. for tardive dyskinesia and drives the...
Market Cap: $13.0B52W Range: $84.23 – $160.18
Congressional Interest in Neurocrine Biosciences, Inc. (NBIX)
5 members of Congress have disclosed 23 trades in Neurocrine Biosciences, Inc. (NBIX), a Healthcare company. The buy/sell breakdown shows 8 purchases versus 15 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
23
Unique Politicians
5
Buys
8
Sells
15
Who in Congress Is Trading NBIX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-06-17 | Lisa McClain | sell | $1K – $15K |
| 2025-06-11 | Lisa McClain | buy | $1K – $15K |